Introduction
Studies of chronic heart failure reported over the last 60 years 1 '" 81 have emphasized the poor prognosis of the condition, at least when left ventricular systolic dysfunction is the cause. Recent clinical trials have also demonstrated that angiotensin-converting enzyme inhibitors, and possibly some other vasodilators, can improve prognosis' 3 ' 9 '. Although there is no dispute about the overall effects of ACE inhibitor therapy on prognosis there is considerable disagreement between studies as to the proportion of patients that die suddenly and the effects of treatment on the relative likelihood of sudden death or death due to circulatory failure.
The reason for these differences are unclear but may relate more to varying definitions rather than real differences between study populations. In the present Manuscript submitted 16 October 1995, and accepted 14 December 1995.
Correspondence. Dr John G F. Cleland, FRCP, FESC, FACC, MRC Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K overview we have identified studies of chronic heart failure that have recorded more than 50 deaths to identify how many studies had defined what was meant by sudden (cardiac) death and death due to circulatory failure. Analysis of the problems of classifying the mode of death was used to generate a new system for classification of death in cardiovascular trials.
Methods
MEDLINE and Current Contents databases and reference lists of relevant papers were reviewed to identify studies reporting more than 50 deaths due to chronic heart failure. MEDLINE was interrogated using the key words 'death' or 'deaths' or 'survival' or 'mortality' and combined with 'heart failure' or 'cardiac failure' or 'ventricular dysfunction'. Five hundred and ninety three studies published before February 1995 were identified using these methods. The abstract of each publication was read to identify original studies that could have reported more than 50 deaths. All relevant papers were then read in full to identify if they should be included.
Only studies of patients with treated, symptomatic chronic heart failure have been included in the present overview. Studies of patients with asymptomatic or untreated left ventricular dysfunction e.g. the SOLVD prevention trial, have not been included. Similarly studies of new-onset heart failure, defined as heart failure of less than one month's duration, such as the AIRE trial, have not been included. Studies that did not report the mode of death, for example the PROMISE trial' 61 and others' 10 ', were also excluded. Where a series of reports derived from the same author or institution within a 5 year period only the last report was accepted The studies selected for this report were reviewed with regards to the number of patients studied, inclusion criteria, duration of follow-up, number of deaths and the mode of death. The various categories used for classifying the mode of death were noted and the definitions of sudden death and death due to circulatory failure were recorded. The data were pooled to determine the proportions of patients reported to die suddenly or with circulatory failure. Average values have been presented as mean ± 1 SD.
Results
Twenty seven studies were identified according to the above criteria'"-371 . These studies are detailed in Table  1 . Most of the studies included patients with chronic heart failure due to various aetiologies including ischaemic heart disease, dilated cardiomyopathy, alcoholic heart muscle disease, hypertensive heart disease or valvular heart disease. Rockman 2S] evaluated only men while all other trials recruited both men and women, though overall 79% of patients were men. The patients included were in NYHA class II-IV. Some studies included patients with severe chronic heart failure only (NYHA class ni-IV)'  2>1M6 '  23 -25 '  29 ' 34 ' 371 . Average left ventricular ejection fraction was reported in 17 studies, and the overall mean was 25% (SD 5%). The mean follow-up was recorded in 22 studies (overall mean 26 ± 21 months). These studies taken together evaluated 10 137 patients, and the total number of deaths was 3909, giving an overall mortality of 38-6%.
Most studies used categories that could be equated with sudden death and death due to circulatory failure, in addition to other causes. The categories and definitions used in studies recording more than 100 deaths are given in Table 2 (data for other studies are available from the authors on request). Deaths due to 'arrhythmias without worsening of heart failure' were reported by the SOLVD group and represent a subset of patients dying suddenly. Deaths due to 'heart failure or arrhythmias with heart failure' were also reported in SOLVD but these deaths cannot be easily classified as sudden or due to circulatory failure. Accordingly pooled data are shown with and without the SOLVD data including the latter group as circulatory deaths ( Table 3) .
The term sudden death was not defined further in four studies' 14 23 ' 281 studies reported that symptoms resistant to therapy had to be present though did not specify the severity of symptoms required. Only one study 131 ' 331 specified that shock or pulmonary oedema had to be present.
Eight studies used a separate category for death subsequent to myocardial infarction, an event occurring prior to death rather than a mode or cause of death, but no study defined the mode (e.g. shock, arrhythmia etc.) or cause (e.g. myocardial rupture) of death subsequent to infarction. Death occurring during sleep was recorded in four studies and was assumed to be sudden in all' 24 Studies were categorized according to how 'sudden' death was defined: instantaneous death or death occurring within 15 min (Table 4{a) ), deaths occurring within 1 h of onset of new symptoms (Table  4 (b)), deaths occurring within 6 h or within 24 h of onset of new symptoms (Table 4 (c)), and studies which defined sudden death only as an 'unexpected' death or where the definition was not available (Table 4 (d)). Data in Table  4 (a) are presented with and without the SOLVD data (see above). Altogether, a total of 3909 deaths occurred in these 27 studies. The proportion of patients dying suddenly and due to progressive heart failure are shown in Table 3 with the SOLVD data included and excluded for the reason stated above. Myocardial infarction, cerebrovascular accidents and pulmonary embolism were not defined as a separate category in most studies, therefore the pooled proportion will not be a valid estimate and hence pooled results are not reported.
Studies that only recruited patients with severe heart failure (NYHA III or IV) reported a slightly higher incidence of sudden death than studies that recruited patients regardless of the severity of heart failure (mean 35% vs 31%). The proportion of patients dying of (progressive) heart failure was 43% in the studies that included only class III-IV patients and 38% in those that recruited patients with milder disease as well. Class III-IV studies had a mean of 22% deaths attributed to other causes as compared to 28% in studies including all patients. The overall mortality in III-IV only studies was 41% as compared to 38% in the group of studies which included milder patients as well. The proportions of sudden, heart failure and other modes of death in relation to the mean left ventricular ejection fraction in different studies are shown in Fig. 1 . This shows that heart failure deaths were more common in studies with a low mean ejection fraction while modes of death other than sudden or heart failure were commoner in studies with a higher mean LVEF.
Discussion
The lack of reporting of and heterogeneity of the definitions for the mode of death in studies of chronic heart failure is the principal finding of this paper. Although this finding is perhaps not unexpected, at least with hindsight, it is of major concern. That the definition of sudden death is heterogeneous has been known for some time, but the lack of any clear definition of death due to circulatory failure in all but one study 131 ' 331 is surprising.
The pooled data show that circulatory failure was the most frequently reported mode of death in chronic heart failure, accounting for up to 42% of all deaths. However, this may be an overestimate as the SOLVD trial's definition of death 'with heart failure or arrhythmia with heart failure' includes many patients that others would have classified as dying suddenly. Nonetheless, even excluding the SOLVD data, death due to circulatory failure remains the most commonly reported mode of death (39% of all deaths). Sudden death accounted for 32% to 34% of deaths depending on inclusion or exclusion of the SOLVD data.
Evolving classifications of the way in which patients die is not a matter of semantics and is of real clinical importance. Knowing accurately how patients die could have a major bearing on new strategies to reduce mortality in chronic heart failure further. Prevention of sudden death prior to the onset of terminal ventricular dysfunction may require a different strategy to the prevention of circulatory failure.
The lack of any clear definition of death due to circulatory failure needs to be rectified. As circulatory failure implies that the pump has failed this could be narrowly defined as cardiogenic shock or intractable pulmonary oedema. It could be argued that this definition is too narrow and that many patients die in a low output state albeit with a terminal sudden event. Such deaths could be recorded as sudden but with clarification of the clinical status prior to death. Defining the severity of heart failure prior to death, by the level of symptoms or amount of therapy required, and worsening heart failure, by a change in symptoms or therapy would help identify patients in whom treatment for worsening heart failure might have prevented sudden death. Sudden death is difficult to define. A definition based predominantly on exclusion of other modes of death may be preferred. Thus, sudden cardiac death could be defined as death in the absence of terminal pump failure, stroke or non-cardiac causes of death. Most patients would be expected to be able to call for help or to be roused from sleep if a non-sudden mode of death were operating and it is not unreasonable to regard such patients as dying suddenly. A patient dying before help can even be requested does not have an opportunity for therapeutic intervention regardless of the actual cause of that mode of death and could legitimately be considered to have died suddenly.
It is illogical to define sudden death according to a span of time from a change in symptoms to the time of death. For instance, a patient who develops a myocardial infarction and cardiogenic shock followed by death 1 h later clearly has a different mode of death from the concept of sudden instantaneous death. Such a patient might have benefited from thrombolysis or emergency revascularization.
It is important not to confuse the mode of death and the cause of death although few studies attempt this distinction. The term sudden death is often used to mean arrhythmic death, although the evidence that the majority of sudden deaths are due primarily to arrhythmias that the majority of sudden deaths in the general population are due to coronary occlusion rather than primarily arrhythmic. Sudden death may be due to tachy-or bradyarrhythmia, coronary occlusion, electromechanical dissociation, myocardial rupture or stroke. It is also possible that the cause of sudden death depends on the severity of heart failure. Pulmonary embolism could be the most important cause of sudden death in severe heart failure 1401 , arrhythmias in mild to moderate heart failure with dilated cardiomyopathy and coronary occlusion in similar patients with heart failure due to ischaemic heart disease. Similarly, the onset of atrial fibrillation, ventricular tachycardia or a recurrent myocardial infarction may cause progressive deterioration in pump function. All deaths due to pump failure are not due to progressive ventricular remodelling.
The severity of heart failure may alter the recorded mode of death. Patients with severe heart failure are a selected group who have already demonstrated 'resistance' to dying suddenly. Alternatively, there may be a bias by doctors against recording death as sudden when severe heart failure is already present. Milder cases appeared more likely to die of modes other than sudden death or death due to progressive heart failure ( Fig. 1) . This is consistent with the better prognosis of patients with mild heart failure and therefore increased likelihood of intercurrent events. However, analysis of data from multiple studies may introduce a number of confounding factors and it is inappropriate to draw any firm conclusion from the data presented here.
Myocardial infarction is a key event to recognise in patients who subsequently die but should not be confused with the mode of death. . Of those that die some will die of cardiogenic shock or in pulmonary oedema, that is circulatory failure, while others will die suddenly of arrhythmias or cardiac rupture. Thus, it is important to know if and when a myocardial infarction occurred but the mode of death should also be recorded.
Surprisingly, an important, simple feature lacking in most studies is a record of where the patient died. If patients die in hospital this implies that some event anticipated their death and that an opportunity may exist to intervene. It is likely that most patients who die in hospital with heart failure are admitted for worsening symptoms or signs, aborted out-of-hospital sudden death, syncope or recurrent myocardial infarction. Opportunities to intervene in each of these situations exist.
The incidence of stroke in CHF studies is low, assuming that stroke does not constitute a large proportion of sudden deaths. Little is known about whether the strokes that did occur were thrombotic, embolic or haemorrhagic. The low incidence of stroke may reflect the fact that patients are dying of cardiac causes before strokes have had time to occur 142 " 44 '. Treatments for chronic heart failure also reduce blood pressure and this could reduce the risk of stroke. Alternatively, it is possible that a high proportion of patients with chronic Eur Heart J, Vol. 17, September 1996 of death or both? Ultimately practicality and clinical utility will be important in denning how death in studies of heart failure is reported. One possible scheme is shown in Fig. 2 . This way of classifying death has been successfully piloted in the AIRE and NETWORK studies; reports from both these studies will soon be available.
